Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Tvardi Therapeutics, Inc. (TVRD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: TVRD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $56.2
1 Year Target Price $56.2
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -84.82% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 242.26M USD | Price to earnings Ratio - | 1Y Target Price 56.2 |
Price to earnings Ratio - | 1Y Target Price 56.2 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 3.74 - 43.65 | Updated Date 11/18/2025 |
52 Weeks Range 3.74 - 43.65 | Updated Date 11/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 221232847 | Price to Sales(TTM) - |
Enterprise Value 221232847 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 9360900 | Shares Floating - |
Shares Outstanding 9360900 | Shares Floating - | ||
Percent Insiders 27.53 | Percent Institutions 2.76 |
Upturn AI SWOT
Tvardi Therapeutics, Inc.
Company Overview
History and Background
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer. The company was founded in 2020 by a team of experienced scientists and entrepreneurs. Significant milestones include the initiation of clinical trials for their lead candidate, TVD001, and securing Series A and B funding rounds.
Core Business Areas
- Oncology Therapeutics Development: Tvardi Therapeutics is primarily engaged in the research and development of small molecule therapies targeting specific oncogenic pathways. Their core focus is on developing orally available drugs with a favorable safety profile for patients with various types of cancer.
Leadership and Structure
Tvardi Therapeutics has a leadership team comprised of experienced professionals in drug development, clinical research, and business operations. The company operates with a lean, agile structure to efficiently advance its pipeline.
Top Products and Market Share
Key Offerings
- Product Name 1: TVD001 - Description: TVD001 is a small molecule inhibitor targeting a specific cellular pathway implicated in cancer growth and progression. It is currently in clinical trials for various solid tumors. Market Share Data: Not applicable at this early clinical stage. Competitors: Various companies developing targeted cancer therapies, including those targeting similar pathways.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly in oncology, is characterized by rapid innovation, high R&D costs, and a significant unmet medical need. The market is driven by the discovery of new molecular targets and the development of precision medicines. Regulatory hurdles and clinical trial success rates are key factors.
Positioning
Tvardi Therapeutics is positioned as an emerging player in the oncology therapeutics space, focusing on a novel mechanism of action. Their competitive advantage lies in their proprietary technology and the potential for a differentiated therapeutic profile.
Total Addressable Market (TAM)
The TAM for oncology therapeutics is substantial, measured in hundreds of billions of dollars globally. Tvardi Therapeutics' position within this TAM is currently nascent, with potential to address specific patient populations within various cancer types as their pipeline matures.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach with a proprietary mechanism of action.
- Experienced leadership team with a strong track record in drug development.
- Focus on orally available small molecules, potentially offering patient convenience.
- Secured significant funding to advance clinical programs.
Weaknesses
- Early-stage clinical development, high risk of trial failure.
- Limited historical financial performance due to its early stage.
- Reliance on a single lead candidate (TVD001) at this stage.
- Potential manufacturing challenges for novel compounds.
Opportunities
- Significant unmet need in various cancer indications.
- Potential for strategic partnerships and collaborations.
- Advancements in precision medicine and biomarker identification.
- Expansion into new cancer types based on preclinical data.
Threats
- Clinical trial failures leading to program discontinuation.
- Competition from established pharmaceutical companies and other biotechs.
- Regulatory hurdles and lengthy approval processes.
- Changes in healthcare reimbursement policies.
Competitors and Market Share
Key Competitors
- Must be publicly traded companies for market share comparison. Tvardi Therapeutics is privately held.
- Therefore, direct competitors with publicly available market share data for Tvardi's specific niche are difficult to pinpoint accurately without more product-specific information.
Competitive Landscape
The competitive landscape for oncology therapeutics is highly dynamic and crowded. Tvardi Therapeutics competes by aiming to develop therapies with a novel mechanism of action and a potentially improved efficacy and safety profile compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Tvardi Therapeutics has experienced growth in its operational capacity and scientific team since its inception, marked by progress in its R&D programs and successful fundraising efforts.
Future Projections: Future projections are dependent on the success of ongoing and future clinical trials and subsequent regulatory approvals. Analyst estimates are not yet widely available for this early-stage company.
Recent Initiatives: Key recent initiatives include the advancement of TVD001 into clinical trials and the securing of significant venture capital funding.
Summary
Tvardi Therapeutics is an early-stage biopharmaceutical company with a promising novel approach to oncology treatment. Its strengths lie in its innovative science and experienced team, but it faces significant risks inherent in clinical development. Capitalizing on unmet medical needs and potential partnerships will be crucial for its future success, while navigating the competitive and regulatory landscape remains a key challenge.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and publicly available information.
- Industry analysis reports (general).
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. Tvardi Therapeutics, Inc. is a privately held company, and detailed financial and market share data may be limited. This information is for informational purposes only and does not constitute investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tvardi Therapeutics, Inc.
Exchange NASDAQ | Headquaters Sugar Land, TX, United States | ||
IPO Launch date 2014-01-31 | CEO & Director Dr. Imran Alibhai Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://tvarditherapeutics.com |
Full time employees 12 | Website https://tvarditherapeutics.com | ||
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.